Prasad S. Adusumilli: Featured News

Memorial Sloan Kettering thoracic surgeon Prasad Adusumilli
New Finding Could Predict Which People with Lung Cancer Will Benefit from Chemotherapy
Researchers identify a biomarker that could predict which lung cancer patients will respond to chemotherapy.
Memorial Sloan Kettering surgeon Prasad Adusumilli
CAR T Cell Therapy Shows Promise for Treating Mesothelioma
A combination immunotherapy approach using CAR T cells could be an effective new way to treat mesothelioma.
Cell Therapy with Dr. Prasad Adusumilli
Cell therapy has made strides in hematology and oncology and has recently shown promise in thoracic oncology. In this episode of Lung Cancer Considered host, Dr. Narjust Duma delves into this emerging therapy with guests Dr. Ben Creelan, associate professor of medicine at the University of South Florida, thoracic oncologist at Moffitt Cancer Center and Dr. Prasad Adusumilli, deputy chief and attending of the thoracic service, vice chair for translational research in the department of surgery at Memorial Sloan Kettering Cancer Center.
Clinical Update
Epidural analgesia for patients with non-small cell lung cancer
Epidural Analgesia Unnecessary in Minimally Invasive Lobectomy
The routine use of epidural analgesia for patients with non-small cell lung cancer who undergo a minimally invasive lobectomy is not warranted.
Cell Therapy and Cell Engineering Facility
T Cell Attack: Taking Down Cancer with Immunotherapy
MSK physician-scientist Prasad Adusumilli is focused on developing more-effective immunotherapy approaches for treating tumors in the chest.
In the Clinic
Doctor and patient looking at x-ray of lungs.
Older Age Is Not a Limiting Factor for Lung Cancer Surgery
Learn why surgery is still a good option for older patients with early-stage lung cancer.
Michel Sadelain and Prasad Adusumilli
Immunotherapy Shows Promise for Treating Solid Tumors in the Chest
A study in mouse models suggests how modified T cells may be used to treat tumors in the area just outside the lungs.
Thoracic surgeon and immunotherapy expert Prasad Adusumilli
Combination Immunotherapy Boosts CAR T Cell Approach for Solid Tumors
Combining checkpoint blockade with engineered T cells may lead to longer-lasting results in patients with breast cancer, lung cancer, and other solid tumors.
In the News
New Biotech Startup Will Pit the Immune System Against Cancer
Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.